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Abstract
Background—Neutrophil expression of the Fcγ receptor I (CD64) is upregulated in adult
patients with clinically active inflammatory bowel disease (IBD). We tested the relationship of
CD64 with mucosal inflammation and clinical relapse in pediatric Crohn's disease (CD).
Methods—In a cohort of 208 newly diagnosed CD and 43 non-IBD controls, ileal expression of
FcγRI/S100A9 was determined by RNA sequencing from biopsies obtained at ileocolonoscopy. In
a second cohort, we tested for the peripheral blood polymorphonuclear neutrophil (PMN) CD64
index from 26 newly diagnosed CD, 30 non-IBD controls and 83 children with established CD.
Results—Ileal FcγRIA mRNA expression was significantly elevated in CD at diagnosis
compared with non-IBD controls (p<0.001), and correlated with ileal S100A9 (calprotectin)
expression (r=0.83, p<0.001). The median(range) PMN CD64 index for newly diagnosed CD was
2.3(0.74-9.3) compared with 0.76(0.39-1.2) for non-IBD controls (p<0.001) with 96% sensitivity
and 90% specificity at the cut point of 1.0. The PMN CD64 index significantly correlated with
mucosal injury as measured by the Simple Endoscopic Score-CD (SES-CD, r=0.62, p<0.001). CD
patients in clinical remission receiving maintenance therapy with a PMN CD64 index <1.0 had a
sustained remission rate of 95% over the following 12 months compared with 56% in those with a
PMN CD64 index >1.0 (p<0.01).
Conclusions—An elevated PMN CD64 index is associated with both mucosal inflammation and
an increased risk for clinical relapse in pediatric CD. The PMN CD64 index is a reliable marker
for sustained remission in CD patients receiving maintenance therapy.
Keywords
innate immune system in IBD; Fc gamma receptor; CD64 index; pediatric Crohn's disease;
biomarker
Introduction
Ongoing mucosal injury in Crohn's disease (CD) is currently assessed indirectly with
subjective disease specific clinical activity indices, by relatively insensitive blood
biomarkers or via gastrointestinal-specific fecal markers. Although fecal calprotectin and
lactoferrin have been shown to correlate with intestinal inflammation,1,2 C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR) remain the most commonly utilized
markers to detect inflammation in CD. Despite continued advances, limitations of the
current CD biomarkers (blood or fecal) cause clinicians to rely on costly tests including
magnetic resonance enterography (MRE) or invasive endoscopy as both tools provide
supportive evidence of intestinal inflammation during periods of overt clinical relapses.
However, persistent intestinal inflammation can also be seen during periods of clinical
remission.3,4 Treatment decisions that rely on clinical symptoms alone without objective,
less invasive markers of persistent intestinal inflammation may increase the risk of CD
progression and disease related complications.5
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As a chronic inflammatory disorder with periods of clinical remission and relapses, the goal
of CD therapy is to improve the patient's quality of life and prevent persistent inflammation
which can lead to CD complications including strictures, fistulae and abscesses. There is
growing evidence that achievement of intestinal healing alters the natural course of CD.
Mucosal healing (MH) has been associated with reduced rates of hospitalization, lower
relapse rates and decreased need for surgery.6-8 Although a single established definition for
this important clinical endpoint has not been formed, MH is usually defined as complete
resolution of intestinal ulcerations during repeat endoscopy.9,10 Equipped with a cost
effective, sensitive and rapid biomarker to detect MH, clinicians could potentially improve
and eventually optimize CD therapeutic regimens and reduce the need for MRE and
endoscopy to detect clinically silent but ongoing intestinal inflammation. In addition, with a
reliable surrogate marker, clinicians could also more accurately differentiate a clinical
relapse from irritable bowel syndrome (IBS) or the presence of other comorbid functional
gastrointestinal disorders (FGID) in quiescent CD which remains a challenge with the
current subjective disease activity indices, especially in pediatric CD.
The Fcγ receptors are expressed by innate immune cells including neutrophils and
monocytes and serve to unite antibody specificity and effector cell functions. Quiescent
polymorphonuclear neutrophils (PMNs) constitutively express the Fcγ receptor II (CD32)
and Fcγ receptor III (CD16) with minimal levels of Fcγ receptor I (CD64) expressed on
neutrophils under basal conditions.11 With active inflammation, neutrophil CD64 is
upregulated early in the innate immune response by interferon (IFN)-γ and granulocyte-
colony stimulating factor (G-CSF).12,13 The central role of CD64, as a high affinity receptor
for immunoglobulin (Ig)G1 and IgG3, is recognition and subsequent clearance of immune
complexes by phagocytosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and
the respiratory burst.11 Upregulation of neutrophil CD64 has been shown to differentiate
symptomatically active from quiescent inflammatory bowel disease (IBD) and relapsing
IBD from infectious enterocolitis in adults.14 However, whether up-regulation of either
tissue or circulating neutrophil CD64 correlated with endoscopic evidence of ongoing
mucosal inflammation or risk of imminent relapse has not been examined.
The primary goal of our investigation was to determine the utility of measuring neutrophil
CD64 expression as a surrogate marker for ongoing intestinal inflammation and whether the
presence of a normal PMN CD64 index during a clinical remission in those receiving CD
maintenance therapy would be associated with sustained remission. We first set out to
explore the relative expression of the Fcγ receptor I (FcγRI) from inflamed CD mucosa
(ileum and rectal). This was followed up by hypothesizing that the PMN CD64 index (a
whole blood assay) could be utilized as a biomarker to test for mucosal inflammation by
correlating the PMN CD64 index with the ileal mRNA expression of FcγRIA and an
endoscopic score of intestinal injury. Finally, we investigated the utility of the PMN CD64
index as a screening biomarker to delineate new diagnosis pediatric CD from non-IBD
related conditions such as IBS.
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Materials and Methods
Patient populations
We studied three groups of patients from two distinct cohorts. Group 1 consisted of children
and adolescents enrolled in the Pediatric Resource Organization for Kids with Inflammatory
Intestinal Diseases (PRO-KIIDS) network RISK Stratification inception cohort study. The
RISK Stratification consortium study is a multicenter cohort of 1794 subjects with newly
diagnosed IBD (of which 1112 patients were diagnosed with CD) and non-IBD controls
(n=373) that were enrolled from 2008-2012 at 28 sites in North America. All RISK subjects
have been well characterized with endoscopic, histologic and disease activity scores and
provided blood, stool and intestinal biopsy specimens at time of diagnosis. For our study, we
have included the 251 and 137 patients for which the respective ileal and rectal biopsy
specimens were obtained during the diagnostic ileocolonoscopy and RNA sequencing
(RNAseq) was performed.
Groups 2 and 3 were enrolled at Cincinnati Children's Hospital Medical Center (CCHMC)
from September 2011 to January 2014 and are referred to collectively as the CCHMC
cohort. Group 2 consisted of patients referred for colonoscopy for the suspicion of IBD. The
patients meeting clinical and histologic criteria for CD15 were entered as newly diagnosed
CD. Patients with chronic gastrointestinal symptoms who were referred for colonoscopy for
the suspicion of IBD and were found to have normal ileocolonoscopic findings by
endoscopy and did not have any chronic evidence of intestinal inflammation on histological
exam were included as the non-IBD controls. Group 3 consisted of CD patients receiving
maintenance therapy that were enrolled either during a routine clinic visit or prior to a
follow up colonoscopy. Blood samples were obtained from each participant. Clinical tests,
including stool samples to determine fecal calprotectin levels or presence of intestinal
pathogens were collected at the discretion of the primary gastroenterologist and were
included in our analysis. The diagnosis of CD and determination of disease phenotype (Paris
classification16) was made by standard clinical, radiological, histological and endoscopic
criteria.15 Disease severity was evaluated by the short pediatric CD activity index (short
PCDAI) with inactive disease defined as a score of less than 15, mild activity defined by
15-30 and scores greater than 30 as moderate to severe.17
Ileal and Rectal Fcγ Receptor I and S100A9 mRNA Expression by RNAseq
Ileal and rectal biopsy specimens were obtained during the diagnostic ileocolonoscopy from
newly diagnosed CD patients and non-IBD controls from the RISK cohort (Group 1). The
biopsy specimens were preserved in RNAlater® (Life Technologies) and then processed for
mRNA utilizing a Qiagen kit (Qiagen, Hilden, Germany). The RNA were then poly(A)
selected and subjected to single-end RNAseq by the Illumina HiSeq 2000 in a CCHMC NIH
supported Digestive Health Center core lab. Reads were aligned using TopHat.18 The
aligned reads were quantified by Avadis® NGS software, (Version 1.3.0, Strand Scientific
Intelligence Inc., San Francisco, CA), using Hg19 as the reference genome and Reads Per
Kilobase per Million mapped reads (RPKM) as an output. The DESeq algorithm was used
for RPKM normalization within Avadis® NGS software and the normalized counts were
log2-transformed and base-lined to the median expression of control samples. Our study was
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specifically interested in the expression of FcγRIA (CD64) and S100A9 (calprotectin) in CD
patients.
Ileal FcγRIA and S100A9 mRNA expression by RT-PCR
Formalin fixed, paraffin embedded (FFPE) ileal biopsy specimens that were previously
obtained during the diagnostic ileocolonoscopy from newly diagnosed CD and non-IBD
controls (Cohort 2) were processed for RNA expression by reverse transcriptase-polymerase
chain reaction (RT-PCR).19 Total RNA was extracted from these clinically archived FFPE
samples by Qiagen miRNeasy FFPE RNA mini kit. With RNA purity verified (~1.9-2.0,
260/280), 500ng of RNA was reverse transcribed into cDNA. Quantitative PCR
amplification was performed with ABI 7900HT amplification system (ABI/Life
Technologies, New York). A set of pre-designed taqman individual expression assays were
used following manufacturers suggested procedures, namely (ABI/Life Technologies
FcγRIA Hs 00417598 and S100A9 Hs 00610058). The expression levels were quantified
after normalizing to the housekeeping gene GAPDH.
PMN CD64 index
Each blood sample from Groups 2 and 3 was processed within 24 hours from collection for
the measurement of the CD64 expression on granulocytes performed by quantitative flow
cytometry on a FACSCalibur (BD Biosciences, San Jose, CA) using the Leuko64™ assay
kit (Trillium Diagnostics, Brewer, ME20). The kit includes fluorescent beads and antibodies
to CD64 and CD163. The lymphocyte, monocyte and granulocyte populations are defined
by their forward and side scatter characteristics along with surface CD163 staining to further
define the monocyte population. The CD64 index is calculated by the ratio of the mean
fluorescent intensity (MFI) of the granulocytes to that of the calibration beads. The
granulocyte specific index is referred as the PMN CD64 index.
Endoscopic Evaluation
Mucosal inflammation was evaluated by the Simple Endoscopic Score-CD21 (SES-CD) for
CD patients who were referred for colonoscopy and had complete endoscopic imaging data
available (Groups 2 & 3). The SES-CD evaluates 5 segmental areas of the ileum and colon
on 4 parameters (ulcer size, percent of ulcerated and affected surfaces, and stenosis) with
each parameter scored from 0-3. The total score from each area is tabulated with inactive
defined as a score of 0-3, mild 4-10, moderate 11-19 and a score of >20 defined as severe
inflammation as has been suggested in a previous investigation.4 The SESCD was tabulated
by the same pediatric gastroenterologist from a streaming video monitor in a retrospective
manner blinded to the results of the PMN CD64 index and disease activity index. For further
analysis of endoscopic scoring assessments and RNA expression, CD patients who had
rectal biopsies obtained for RNAseq analysis were divided into (1, normal) if there were no
histologic and endoscopic abnormality noted, (2, Micro) if the endoscopic exam was normal
but the histology was consistent with CD and (3, Macro) if they had both histologic and
endoscopic findings of CD.
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Statistical Analyses
All statistical analyses were performed using GraphPad PRISM© Version 5. Mann-Whitney
U test was used for comparisons between two groups while the Kruskal Wallis analysis of
variance with Dunn's test for multiple comparisons was used for assessments between more
than two groups. The association between the PMN CD64 index and the short PCDAI,
laboratory assessments, and endoscopic scores were evaluated by the Spearman's rank
correlation coefficient (r) for nonparametric correlations. Receiver operator characteristic
(ROC) curves were performed by plotting sensitivity vs. 1-specificity. Kaplan-Meier
survival curve analysis was performed to test for differences in the rate of clinical relapse in
CD patients over the subsequent 12 months and was stratified by the baseline PMN CD64
index. Data are expressed as median (minimum to maximum range). A p value <0.05 was
considered to be statistically significant.
Ethical Considerations
All subjects and/or their parents/guardians provided informed consent, with subjects over
the age of 11 providing assent prior to collection of study data. The study was approved by
the Institutional Review Board at CCHMC. For the RISK subjects, the Institutional Review
Board at each participating center approved the protocol.
Results
Study Population
Group 1: RISK Cohort—RNAseq analysis was performed from ileal biopsy specimens
from 208 Caucasian patients with newly diagnosed CD and 43 non-IBD controls as well as
from rectal biopsy specimens obtained from 109 newly diagnosed CD and 28 non-IBD
controls. The clinical and demographic characteristics are in Table 1.
Groups 2 & 3: CCHMC Cohort—Group 2 consisted of 56 patients referred for
colonoscopy for the clinical and/or laboratory suspicion of IBD. 26 patients met criteria for
CD and 30 patients were included as non-IBD controls as they had no histological findings
of IBD and had a normal ileocolonoscopy. Patients with mild non-specific acute gastric or
esophageal histologic inflammation were not excluded. Small bowel imaging was performed
in 3/30 non-IBD controls. The final diagnosis for the non-IBD controls included irritable
bowel syndrome (IBS)-constipation (9/30), IBS-diarrhea (3/30), chronic abdominal pain
(9/30), gastroesophageal reflux disease (7/30) and post-infectious (2/30). Group 3 consisted
of 83 patients receiving maintenance therapy for CD. The clinical and demographic
characteristics of the 139 CCHMC patients are in Table 2.
Fcγ Receptor I is Upregulated in Ileal and Rectal Tissue as well as Circulating
Neutrophils in Newly Diagnosed Crohn's Disease—We first asked whether patients
undergoing diagnostic ileocolonoscopy for suspected IBD and found to have CD would up-
regulate FcγRIA in intestinal tissues and CD64 in circulating neutrophils compared to non-
IBD controls. Ileal biopsy specimens obtained from Group 1 colon-only (Paris classification
L2) CD patients and ileal CD (Paris classification L1/L3) showed a significant difference in
the median normalized RPKM FcγRIA mRNA expression compared to the non-IBD control
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patients (p<0.001, Figure 1a). We found there wasn’t a significant difference in ileal
FcγRIA expression between L2 CD and L1/L3 CD. Further, we found a similar relationship
among the ileal expression of S100A9 (calprotectin) among these groups (Figure 1b). We
further investigated the relationship between ileal expression of FcγRIA and S100A9 and
found a significant correlation (Spearman r = 0.83, p<0.001, Figure 1c). To determine if
ileal tissue expression levels of FcγRIA correlated with CD64 expression on the surface of
circulating PMN's in the blood, we performed RTPCR from RNA obtained from FFPE on
14 newly diagnosed CD patients and 6 non-IBD controls. We found a significant Spearman
correlation between the PMN CD64 index from circulating neutrophils and tissue CD64
expression (r = 0.63, p<0.01, Figure 1d).
Rectal FcγRIA mRNA expression was also determined from 109 newly diagnosed CD and
compared to 28 non-IBD controls. The findings were similar to the ileal expression data. We
found the expression of FcγRIA from CD with either endoscopic or histologic proctitis was
significantly elevated compared to non-IBD controls (p<0.001, Figure 2a). We did not find
a significant difference in the median normalized RPKM between the CD patients with a
histologic and endoscopic normal rectum (n=34) and the non-IBD controls. Further, we
found a significant difference between CD with normal rectum and CD with microscopic
proctitis (determined by the histological evaluation, n=20, p<0.05). The S100A9 mRNA
expression displayed a similar pattern to FcγRIA with the exception that there was no
difference in S100A9 expression between CD with microscopic proctitis and CD with a non-
inflamed rectum (Figure 2b). We also found a significant correlation of rectal FcγRIA and
S100A9 among the CD patients (Spearman r = 0.73, p<0.001, Figure 2c).
We then asked whether CD64 would be up-regulated on the surface of circulating
neutrophils from peripheral blood in patients having ileocolonoscopy for suspected IBD
(Group 2). In this group, 26 patients were diagnosed with CD with a median PMN CD64
index of 2.3 (range 0.74-9.3) and a median PMN CD64 index of 0.76 (range 0.39-1.2) in the
30 non-IBD controls (p<0.001, Figure 3a). In the same cohort, 32/56 patients referred for
endoscopy had fecal calprotectin collected. The median(range) fecal calprotectin for 14 non-
IBD controls was 147 mcg/gm (16-670) compared to 1318 mcg/gm (226-2500) for new
diagnosis CD (p<0.001). To evaluate both biomarkers in this cohort, we performed receiver
operator characteristic (ROC) curve analysis. At a cut-off of 1.0, the PMN CD64 index was
96% sensitive and 90% specific in differentiating new diagnosis IBD from non-IBD with a
positive predictive value (PPV) of 89%, a 96% negative predictive value (NPV) and an area
under the curve (AUC) of 0.98 (95% confidence internal, CI of 0.94-1.02, Figure 3b). By
comparison, we performed ROC curve analysis on the 32/56 (57%) patients in Group 2 who
had a fecal calprotectin collected prior to endoscopy. Prior analysis of fecal calprotectin has
suggested that a cut off of >50 mcg/gm should be used to distinguish IBD from IBS with
>250 mcg/gm utilized to determine the presence of large ulcers in CD.1 In our cohort, at a
cut off of 50 mcg/gm, fecal calprotectin was 100% sensitive, 29% specific with a PPV of
64% and a NPV of 100% (AUC 0.96, 95% CI 0.91-1.02) for new diagnosis CD. At a cut off
of 250 mcg/gm, it was 94% sensitive, 64% specific with a PPV of 77% and a NPV of 90%.
In order to compare the test characteristics of both biomarkers in the same patients, we
performed ROC curve analysis for the PMN CD64 index on the 32/56 patients who also had
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a fecal calprotectin collected. We found the PMN CD64 index to be 94% sensitive, 93%
specific with a PPV of 94% and a NPV of 93% at the cut off of 1.0.
The PMN CD64 Index Correlates with Mucosal Inflammation—We next assessed
peripheral blood neutrophil CD64 expression as a marker of endoscopic evidence of
mucosal inflammation in newly diagnosed and CD patients receiving maintenance therapy.
36 CD patients (20 patients in Group 2 and 16 patients in Group 3) had an ileocolonoscopy
performed with video recording to determine the SES-CD. The PMN CD64 index correlated
with the SES-CD (Spearman r = 0.62, p<0.001, Figure 4a). In addition, there was a
significant difference in the median PMN CD64 index and the degree of endoscopic severity
as defined by the SES-CD (Kruskal-Wallis p<0.01, Figure 4b). Next, we evaluated the
correlation of the SES-CD and fecal calprotectin collected in this group (16/36 CD patients)
and found a significant Spearman correlation (r = 0.65, p<0.01). Lastly, the SES-CD
correlated with the short PCDAI (Spearman r = 0.45, p<0.01) and the ESR (Spearman r =
0.59, p<0.05, n=16). However, CRP did not correlate with the SES-CD (Spearman r = 0.34,
p = not significant).
The PMN CD64 Index is Elevated in Clinically Active CD Compared to
Quiescent CD—To evaluate the utility of the PMN CD64 index for disease activity
(which was determined by the short PCDAI) we enrolled 83 CD patients receiving
maintenance therapy (Group 3). The median(range) PMN CD64 index for the 43 active CD
was 1.6 (0.77-8.2) which was significantly elevated compared with the 40 quiescent CD
(median 0.97, range 0.63-2, p<0.001, Figure 5a). Interestingly, when we compared
quiescent CD to the non-IBD controls (median 0.76, range 0.39-1.2), the index also differed
significantly between the two groups (p<0.001).
Next we determined whether the degree of elevation in the PMN CD64 index would be
associated with the clinical severity of IBD flares as assessed by the short PCDAI.
Comparing the neutrophil CD64 expression across disease severity in CD, we found that the
median PMN CD64 index for mild activity (short PCDAI 15-30) was 1.2 (0.77-3.9) and for
moderate-severe disease activity (short PCDAI >30) the median was 2.2 (0.85-8.2, p<0.05).
With further analysis, the PMN CD64 index was shown to significantly correlate with the
short PCDAI (Spearman r = 0.56, p<0.001, Figure 5b).
We also determined whether the PMN CD64 index from Groups 2 & 3 would be associated
with other laboratory markers of inflammation. The PMN CD64 index directly correlated
with CRP (Spearman r = 0.76, p<0.001) and ESR levels (Spearman r = 0.66, p <0.001
Figure 6a, 6b). The CD64 index modestly correlated with the absolute neutrophil count
(ANC, Spearman r = 0.32, p<0.01). Given the correlation between ileal and rectal
expression of FcγRIA and S100A9, we examined the relationship of the PMN CD64 index
with fecal calprotectin in the CCHMC cohort (Groups 2 & 3) and also detected a significant
correlation (Spearman r = 0.54, p<0.001, Figure 6c) in 53 patients that had both biomarkers
measured. We found that the median PMN CD64 index did not differ by CD location (ileal,
colonic or ileocolonic).
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We also performed ROC analysis to determine the utility of the PMN CD64 index to
accurately identify clinically active disease as determined by the short PCDAI and found at
a cut point of 1.0, the sensitivity was 85% with a specificity of 55%, PPV of 74% and a
NPV of 71%. (AUC 0.83, 95% CI 0.75-0.91, p<0.001 Figure 6d). Likewise using the short
PCDAI to define active inflammation, a fecal calprotectin of >250 mcg/gm was 86%
sensitive and 50% specific with a PPV of 89% and a NPV of 43% (AUC 0.85, 95% CI
0.7-1.0).
PMN CD64 Index and Clinical Activity Index Predict Likelihood of Sustained
Remission—Given the correlation between the PMN CD64 index and endoscopic severity
in CD, we determined whether normalization of the index would be associated with
sustained remission. In Group 3, 40 CD patients had clinically inactive disease (defined by a
short PCDAI <15) at time of the CD64 index measurement. Of those 40 patients, we had
complete follow up data for the following 12 months on 37 patients. We found that CD
patients receiving maintenance therapy in clinical remission who had a PMN CD64 index >
1.0 experienced a relapse rate of 44% during one year follow-up, compared with a relapse
rate of 5% in those with a PMN CD64 index < 1.0 (p<0.01, Figure 7).
Discussion
Activated neutrophils play a crucial role in host defense via recognition, phagocytosis, and
elimination of invading pathogens. The neutrophil phagocytic responses are initiated by
specific receptors that recognize intestinal microbes such as the toll like receptors (TLR) and
C-type lectins or by Igopsonized bacteria through the Fcγ receptors.22 Likewise, CD is
characterized by a mixed inflammatory cell infiltrate including activated neutrophils that as
a result of a dysregulated response to the local gut microbiota produce proinflammatory
cytokines, chemokines, T cell activation and reactive oxygen species that contribute to
mucosal injury.23-25 Our investigation demonstrated that active CD was significantly
associated with an upregulation of CD64 on circulating neutrophils and an increased
expression of FcγRIA from ileal and rectal biopsy specimens.
Prior investigations have shown that quantitative analysis of CD64 can be used to
distinguish chronic inflammatory conditions from healthy controls.14,26-28 Tillinger et al. not
only evaluated CD64 as a marker to differentiate acute, intestinal infection from clinically
active IBD, but also showed that CD64 discriminated clinically active disease from
quiescent IBD in adult patients.14 Although they did show evidence of CD64 positive
neutrophils infiltrating the lamina propria of the colon in active CD by
immunohistochemistry,14 our investigation further demonstrates that the mRNA expression
of FcγRIA from ileal and rectal tissue is also significantly elevated above controls. More
recently, Wojtal et al. showed that non-response to anti-TNFα therapy in IBD patients was
associated with an elevation of CD64 mRNA expression from post-treatment colonic biopsy
specimens.29 Whether mucosal expression of FcγRIA can provide prognostication for anti-
TNFα response will need to be further investigated. Although limited to 20 patients, our
correlation between the PMN CD64 index and ileal expression of FcγRIA suggests that the
PMN CD64 index can be utilized as a marker of mucosal treatment response.
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Fecal calprotectin was developed as a non-invasive surrogate biomarker of intestinal
inflammation as it correlated with the fecal excretion of indium-111-labeled
granulocytes30,31 and has been validated as a surrogate stool marker for endoscopic lesions
in IBD.1 However, fecal calprotectin has also been associated with elevations with non-
steroidal anti-inflammatory drug (NSAID) use, celiac disease, allergic colitis and colonic
polyps.32,33 Similarly, the PMN CD64 index has been utilized in other disciplines, most
notably in the early recognition of neonatal sepsis34 and other bacterial infections in
children.35 When we compared these two biomarkers in their ability to identify new
diagnosis CD, the PMN CD64 demonstrated a superior specificity when a fecal calprotectin
cut off of 50 mcg/gm was utilized (90% specificity for PMN CD64 index compared to 29%
specificity for fecal calprotectin). While a fecal calprotectin level of >50 mcg/gm has been
suggested as the cut point to distinguish IBD from non-IBD, we found that only 4/14 non-
IBD controls had a fecal calprotectin <50 mcg/gm. We found 9/14 non-IBD controls had a
fecal calprotectin >100 mcg/gm (median 299, range 105-670) and 5/14 >250 mcg/gm. The
final diagnosis for those 9 patients with a fecal calprotectin >100 mcg/gm included GERD
(5/9), IBS-constipation (2/9) and chronic abdominal pain (2/9). Evaluation of the small
bowel was at the discretion of the treating clinician and was not completed in any of the 9
subjects with an elevated fecal calprotectin. For cohort 2, the mean time of fecal calprotectin
collection prior to endoscopy was 18 days (standard deviation 15).
With the increased use of anti-TNFα therapy, clinical trials have shown that MH is
associated with improved outcomes and proposed by some investigators that MH should be
the primary endpoint for all IBD therapeutics.36,37 Taken one step further in CD, deep
remission (defined as a CD activity index less [CDAI] than 150 and complete mucosal
healing as defined by endoscopy) has been shown in adults with CD to be related with
improved long term disease specific quality of life, fewer flares and hospitalizations, greater
work productivity and less activity impairment compared to MH alone.38 With these goals,
several biomarkers and testing modalities (disease index, and imaging,) have been proposed
to less invasively evaluate for MH. Fecal calprotectin levels have proven to be superior to
either CRP or the subjective clinical indices in identifying endoscopic remission.39 In our
study, the PMN CD64 index correlated well with the degree of macroscopic injury in CD (r
= 0.62) and is similar to the published data with fecal calprotectin and the SES-CD(r =
0.75).4 With a closer review of our cohort with endoscopic scoring, we found the largest
discrepancies between SES-CD and the PMN CD64 index was seen in those CD patients
with significant small bowel disease who had a significantly elevated PMN CD64 index but
a relatively low SES-CD score. In fact, in our final analysis, we excluded 2 newly diagnosed
CD patients who both had a calculated SES-CD score of only 2, which by the Schoepfer et
al40 scoring system would have been classified as inactive. Upon further imaging of the
small bowel, both of these treatment naïve CD patients were found to have extensive small
bowel inflammation as well as a markedly elevated PMN CD64 index and fecal calprotectin.
This inconsistency illustrates the limitation of the SES-CD and other endoscopic scores with
their failure to account for extensive small bowel inflammation in CD. There has been great
interest in developing a CD intestinal score which will take into account both
ileocolonoscopic findings as well as small bowel imaging techniques41
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Studies have found that 57-59% of CD patients have concurrent IBS.42,43 Moreover, with
the similarities of gastrointestinal symptoms shared in active CD and IBS, determining
disease activity in a patient with a comorbidity of CD and IBS poses a significant diagnostic
dilemma. An objective biomarker such as the PMN CD64 index provides a potentially
improved opportunity to determine MH or clinically silent CD with ongoing intestinal
inflammation without relying on endoscopy and disease specific activity indices. Our study
was not designed to differentiate active CD without IBS from quiescent CD with IBS,
however, the significant correlation seen between the PMN CD64 index and both the SES-
CD and ileal expression of FcγRIA suggests additional utility of the CD64 index as a screen
for active intestinal inflammation in CD.
Our investigation has demonstrated that the PMN CD64 index determined by whole blood
analysis can provide useful data to the clinician treating pediatric CD. Larger, prospective
studies will be needed to determine if improved outcomes are seen by defining deep
remission in pediatric CD as a short PCDAI <15 and a PMN CD64 index <1.0. We found
that those CD meeting these parameters sustained a 95% remission rate over the following
year. We were not able to perform a similar analysis for fecal calprotectin in our cohort
given the small number of patients with the biomarker collected, but studies have shown that
a fecal calprotectin >400 mcg/gm in those with clinically quiescent IBD is associated with
increased risk of disease relapse in the following year.44,45
The major strength of our study is the large sample size of patients who had RNAseq
performed from the ileum and rectum. Given the heterogeneity of collecting ileal biopsy
across this large multicenter inception cohort, we could not confirm if ileal biopsies sent for
RNAseq analysis included Peyer's patches. However, given the large numbers of non-IBD
controls and the similarities between the rectal and ileal RNA expression for both genes in
CD, this limitation may not be contributory in the final interpretation of the ileal RNAseq
data. The relative small sample size (n=36) and the retrospective viewing of the
ileocolonoscopy to determine the SES-CD by a single endoscopist as well as the inability of
the SES-CD to reflect the total inflammatory burden will require larger, prospective
validation prior to widespread use of the PMN CD64 index as surrogate marker of MH.
Although the PMN CD64 index assay is a commercially available assay and can be
processed in less than one hour, it requires the use of a flow cytometer which may not be
available at every laboratory. The patient charge at our institution to perform the PMN
CD64 index in our CLIA approved clinical laboratory is $159.00 with a <24 hour
turnaround time compared to an institution charge to the patient of $477.00 for fecal
calprotectin with results arriving <5 days. Our institution does not currently offer point-of-
care fecal calprotectin testing, however, this technology is available with much faster results
and good correlation to the standard ELISA assays.46
Although CD64 has been investigated in adult IBD, this is the first study to investigate
CD64 up-regulation in pediatric CD by ileal and rectal RNAseq as well as to correlate the
PMN CD64 index on circulating neutrophils and the degree of endoscopic evidence of
mucosal inflammation. The significant correlation between the PMN CD64 index and the
SES-CD, ileal CD64 expression and sustained remission offers an exciting opportunity to
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monitor the PMN CD64 index as the standardized marker of treatment response and deep
remission in CD.
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Figure 1. Ileal Fcγ Receptor I expression in newly diagnosed Crohn's disease
mRNA expression level of FcγRIA and S100A9 were determined by RNA sequencing of
ileal biopsy specimens obtained from newly diagnosed colon-only CD (n=37), ileal/
ileocolonic CD (n=171) and non-IBD controls (n=43). A) Ileal FcγRIA expression from CD
patients was compared to non-IBD controls while B) S100A9 expression was also evaluated
in the same groups. C) The association between ileal FcγRIA and S100A9 expression in
newly diagnosed CD was tested. D) Ileal expression of FcγRIA was determined by RT-PCR
and obtained from biopsy specimens on newly diagnosed CD and non-IBD controls. The
FcγRIA expression was then compared to the surface expression of CD64 on circulating
neutrophils. RNA sequencing values are normalized log2 transformed. Data are shown as
the median and interquartile range. Differences between the groups were tested by Kruskal
Wallis with Dunn's test for multiple comparisons. Spearman rank (r) coefficient performed
for correlations. ***p<0.001.
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Figure 2. Rectal Fcγ Receptor I expression in newly diagnosed Crohn's disease
mRNA expression level of FcγRIA and S100A9 were determined by RNA sequencing of
rectal biopsy specimens obtained from newly diagnosed CD and non-IBD controls. CD
normal rectum (n=34), CD microscopic rectal inflammation (n=20), and CD macroscopic
rectal inflammation (n=55). A) Rectal FcγRIA expression from CD patients was compared
to non-IBD controls while B) S100A9 expression was also evaluated in the same groups. C)
The association between rectal FcγRIA and S100A9 expression in newly diagnosed CD was
tested. RNAseq values are normalized log2 transformed. Data are shown as the median and
interquartile range. Differences between groups were tested by Kruskal Wallis with Dunn's
test for multiple comparisons. Spearman rank (r) coefficient performed for correlations.
Normal, no endoscopic or histological features of Crohn's, Micro, endoscopic normal with
histologic features of Crohn's. Macro, both endoscopic and histologic features of Crohn's.
*<0.05, **<0.01, ***<0.001, ns, non-significant.
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Figure 3. Peripheral blood neutrophil CD64 expression for newly diagnosed Crohn's disease
Circulating neutrophil expression of CD64 was determined by flow cytometry and is
reported as the PMN CD64 index. A).The PMN CD64 index was measured from 30 non-
IBD controls and 26 newly diagnosed CD patients. B) Receiver operator characteristic
analysis was performed for the PMN CD64 index to determine the cut point for this marker
relative to the diagnosis of CD by ileocolonoscopy. At a CD64 index of 1.0, the PMN CD64
index was 96% sensitive and 90% specific. Data shown as the median and interquartile
range. Differences between the groups were tested by Mann Whitney U. AUC, area under
the curve. CI, confidence interval. ***p<0.001.
Minar et al. Page 17
Inflamm Bowel Dis. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. Relationship of the PMN CD64 index and mucosal inflammation in Crohn's disease
Circulating neutrophil expression of CD64 was determined by flow cytometry and is
reported as the PMN CD64 index while endoscopic disease severity was determined by the
Simple Endoscopic Score-Crohn's disease (SES-CD). A) The association between the PMN
CD64 index and the SES-CD (n=36). B) The PMN CD64 index stratified by the intensity of
intestinal inflammation as determined by the SES-CD. Spearman rank (r) coefficient was
performed for correlation. Differences between groups were tested by Kruskal Wallis
analysis of variance with Dunn's test for multiple comparisons and shown as median and
interquartile range. *p<0.05***p<0.001
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Figure 5. The PMN CD64 index and clinical disease activity
The PMN CD64 index was determined by flow cytometry. Disease quiescence for CD was
defined by a short PCDAI <15. A) PMN CD64 index for quiescent and active CD is shown.
B) Correlation between the PMN CD64 index and the short PCDAI. Data shown as the
median and interquartile range. Statistical significance was determined by Mann Whitney U.
Spearman rank coefficient (r) performed for correlation. ***p<0.001.
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Figure 6. CD64 index and inflammatory Blood and Fecal Biomarkers utilized in Crohn's
PMN CD64 index was determined by flow cytometry. The inflammatory markers ESR, CRP
and fecal calprotectin were measured in the CCHMC clinical laboratory. Analyses were
performed from Cohorts 2 and 3 to compare the PMN CD64 index with A) CRP, B) ESR
and C) fecal calprotectin. D) Receiver operator characteristic analysis for the PMN CD64
index for clinically active CD as determined by short PCDAI. At a CD64 index of 1.0 the
test is 85% sensitive and 56% specific (p<0.001) for active CD. Spearman rank (r)
coefficient performed for correlations. AUC, area under the curve; CI, confidence interval.
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Figure 7. The PMN CD64 index and sustained clinical remission
The PMN CD64 index was determined by flow cytometry in 37 CD patients receiving
maintenance therapy and in clinical remission (short PCDAI < 15). Rates of clinical relapse
were determined during one year follow-up. Kaplan-Meier survival curve analysis was
performed and is shown for CD patients stratified by a CD64 index of 1.0.
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Table 1
RISK cohort clinical and demographic characteristics.
Group 1
Ileal mRNA Rectal mRNA
Non-IBD Controls (n=43) Crohn's Disease (n=208) Non IBD
Controls
(n=28)
Crohn's Disease (n=109)
Gender M/F 28/15 128/80 17/11 73/36
Median Age (range) 11 (2-17) 12 (2-17) 11 (2-17) 12 (2-17)
Age at diagnosis
        0-<10 years 58 26
        10-<17 years 150 83
Location
        Distal 1/3 ileum 46 23
        Colonic 37 19
        Ileocolonic 125 67
Behavior
        Inflammatory (Nonstricturing
& Nonpenetrating)
208 109
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Table 2
CCHMC cohort clinical and demographic characteristics.
Group 2 Group 3
Non-IBD Controls (n=30) New Diagnosis
Crohn's (n=26)
Crohn's Disease (n=83)
Gender M/F 14/16 19/7 51/32
Median Age (range) 14 (6-18) 13 (6-18) 15 (1-24)
Active/inactive 26/0 43/40
Crohn's Disease
Age at diagnosis
        0-<10 years 7 28
        10-<17 years 17 52
        17-40 years 2 3
Location
        Distal 1/3 ileum 5 11
        Colonic 7 22
        Ileocolonic 14 50
Behavior
        Inflammatory (Nonstricturing & Nonpenetrating) 23 53
        Stricturing 0 10
        Penetrating 3 8
        Both penetrating/Stricturing 0 12
Current Therapy
        Corticosteroids 24
        IM (6-MP, MTX) 49
        Anti-TNFα 39
        Anti-TNFα + IM 17
        5-ASA 38
Disease activity was defined using the short pediatric Crohn's disease activity index. Crohn's disease age at diagnosis, disease location and behavior
were defined using the Paris classification. IM, immunomodulator; 6-MP, 6-mercaptopurine; MTX, methotrexate; TNF, tumor necrosis factor; 5-
ASA, 5-aminosalicylic acid
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